The Mitogen-Activated Protein Kinase p38α Regulates Tubular Damage in Murine Anti-Glomerular Basement Membrane Nephritis

PLoS ONE

Volumn 8, Issue 2, 2013, Pages

  Müller, Ralf ^a   Daniel, Christoph ^a   Hugo, Christian ^b   Amann, Kerstin ^a   Mielenz, Dirk ^a   Endlich, Karlhans ^c   Braun, Tobias ^a   van der Veen, Betty ^d   Heeringa, Peter ^d   Schett, Georg ^a   Zwerina, Jochen ^a  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^b DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^c UNIVERSITY OF GREIFSWALD   (Germany)

^d UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 1; INTERLEUKIN 10; INTERLEUKIN 8; MITOGEN ACTIVATED PROTEIN KINASE 14; MONOCYTE CHEMOTACTIC PROTEIN 1; MONOCYTE CHEMOTACTIC PROTEIN 3; RANTES; TUMOR NECROSIS FACTOR;

ACUTE KIDNEY FAILURE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVATION; ENZYME REGULATION; GLOMERULUS BASEMENT MEMBRANE; HISTOPATHOLOGY; KIDNEY FIBROSIS; KIDNEY TUBULE DISORDER; KNOCKOUT MOUSE; MOUSE; NEPHRITIS; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; RENAL PROTECTION; UPREGULATION;

ANIMALS; AUTOANTIBODIES; CYTOKINES; DISEASE MODELS, ANIMAL; ENZYME ACTIVATION; GENE DELETION; GENE EXPRESSION REGULATION; GLOMERULONEPHRITIS; INFLAMMATION MEDIATORS; KIDNEY GLOMERULUS; KIDNEY TUBULES; LEUKOCYTES; MICE; MICE, KNOCKOUT; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PODOCYTES;

EID: 84874150462     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0056316     Document Type: Article

References (41)

1. Cobb BS, Payne DM, Reynolds AB, Parsons JT, (1991) Regulation of the oncogenic activity of the cellular src protein requires the correct spacing between the kinase domain and the C-terminal phosphorylated tyrosine (Tyr-527). Mol Cell Biol 11: 5832-5838.
2. Ip YT, Davis RJ, (1998) Signal transduction by the c-Jun N-terminal kinase (JNK)-from inflammation to development. Curr Opin Cell Biol 10: 205-219.
3. New L, Han J, (1998) The p38 MAP kinase pathway and its biological function. Trends Cardiovasc Med 8: 220-228.
4. Pearson G, Robinson F, Beers Gibson T, Xu BE, Karandikar M, et al. (2001) Mitogen-activated protein (MAP) kinase pathways: regulation and physiological functions. Endocr Rev 22: 153-183.
5. Johnson GL, Lapadat R, (2002) Mitogen-activated protein kinase pathways mediated by ERK, JNK, and p38 protein kinases. Science 298: 1911-1912.
6. Han J, Lee JD, Tobias PS, Ulevitch RJ, (1993) Endotoxin induces rapid protein tyrosine phosphorylation in 70Z/3 cells expressing CD14. J Biol Chem 268: 25009-25014.
7. Han J, Lee JD, Bibbs L, Ulevitch RJ, (1994) A MAP kinase targeted by endotoxin and hyperosmolarity in mammalian cells. Science 265: 808-811.
8. Tan Y, Rouse J, Zhang A, Cariati S, Cohen P, et al. (1996) FGF and stress regulate CREB and ATF-1 via a pathway involving p38 MAP kinase and MAPKAP kinase-2. EMBO J 15: 4629-4642.
9. Lee JC, Laydon JT, McDonnell PC, Gallagher TF, Kumar S, et al. (1994) A protein kinase involved in the regulation of inflammatory cytokine biosynthesis. Nature 372: 739-746.
10. Jiang Y, Chen C, Li Z, Guo W, Gegner JA, et al. (1996) Characterization of the structure and function of a new mitogen-activated protein kinase (p38beta), J Biol Chem. 271: 17920-17926.
11. Lechner C, Zahalka MA, Giot JF, Moller NP, Ullrich A, (1996) ERK6, a mitogen-activated protein kinase involved in C2C12 myoblast differentiation. Proc Natl Acad Sci U S A 93: 4355-4359.
12. Li Z, Jiang Y, Ulevitch RJ, Han J, (1996) The primary structure of p38 gamma: a new member of p38 group of MAP kinases. Biochem Biophys Res Commun 228: 334-340.
13. Jiang Y, Gram H, Zhao M, New L, Gu J, et al. (1997) Characterization of the structure and function of the fourth member of p38 group mitogen-activated protein kinases. p38delta, J Biol Chem 272: 30122-30128.
14. Kumar S, McDonnell PC, Gum RJ, Hand AT, Lee JC, et al. (1997) Novel homologues of CSBP/p38 MAP kinase: activation, substrate specificity and sensitivity to inhibition by pyridinyl imidazoles. Biochem Biophys Res Commun 235: 533-538.
15. Beardmore VA, Hinton HJ, Eftychi C, Apostolaki M, Armaka M, et al. (2005) Generation and characterization of p38beta (MAPK11) gene-targeted mice. Mol Cell Biol 25: 10454-10464.
16. Sabio G, Arthur JS, Kuma Y, Peggie M, Carr J, et al. (2005) p38gamma regulates the localisation of SAP97 in the cytoskeleton by modulating its interaction with GKAP. EMBO J 24: 1134-1145.
17. Mudgett JS, Ding J, Guh-Siesel L, Chartrain NA, Yang L, et al. (2000) Essential role for p38alpha mitogen-activated protein kinase in placental angiogenesis. Proc Natl Acad Sci U S A 97: 10454-10459.
18. Allen M, Svensson L, Roach M, Hambor J, McNeish J, et al. (2000) Deficiency of the stress kinase p38alpha results in embryonic lethality: characterization of the kinase dependence of stress responses of enzyme-deficient embryonic stem cells. J Exp Med 191: 859-870.
19. Adams RH, Porras A, Alonso G, Jones M, Vintersten K, et al. (2000) Essential role of p38alpha MAP kinase in placental but not embryonic cardiovascular development. Mol Cell 6: 109-116.
20. Engel FB, Schebesta M, Duong MT, Lu G, Ren S, et al. (2005) p38 MAP kinase inhibition enables proliferation of adult mammalian cardiomyocytes. Genes Dev 19: 1175-1187.
21. Jackson JR, Bolognese B, Hillegass L, Kassis S, Adams J, et al. (1998) Pharmacological effects of SB 220025, a selective inhibitor of p38 mitogen-activated protein kinase, in angiogenesis and chronic inflammatory disease models. J Pharmacol Exp Ther 284: 687-692.
22. Badger AM, Griswold DE, Kapadia R, Blake S, Swift BA, et al. (2000) Disease-modifying activity of SB 242235, a selective inhibitor of p38 mitogen-activated protein kinase, in rat adjuvant-induced arthritis. Arthritis Rheum 43: 175-183.
23. Nick JA, Young SK, Brown KK, Avdi NJ, Arndt PG, et al. (2000) Role of p38 mitogen-activated protein kinase in a murine model of pulmonary inflammation. J Immunol 164: 2151-2159.
24. Underwood DC, Osborn RR, Bochnowicz S, Webb EF, Rieman DJ, et al. (2000) SB 239063, a p38 MAPK inhibitor, reduces neutrophilia, inflammatory cytokines, MMP-9, and fibrosis in lung. Am J Physiol Lung Cell Mol Physiol 279: 895-902.
25. Bohm C, Hayer S, Kilian A, Zaiss MM, Finger S, et al. (2009) The alpha-isoform of p38 MAPK specifically regulates arthritic bone loss. J Immunol 183: 5938-5947.
26. Stambe C, Atkins RC, Tesch GH, Kapoun AM, Hill PA, et al. (2003) Blockade of p38alpha MAPK ameliorates acute inflammatory renal injury in rat anti-GBM glomerulonephritis. J Am Soc Nephrol 14: 338-351.
27. Sheryanna A, Bhangal G, McDaid J, Smith J, Manning A, et al. (2007) Inhibition of p38 mitogen-activated protein kinase is effective in the treatment of experimental crescentic glomerulonephritis and suppresses monocyte chemoattractant protein-1 but not IL-1beta or IL-6. J Am Soc Nephrol 18: 1167-1179.
28. Damjanov N, Kauffman RS, Spencer-Green GT, (2009) Efficacy, pharmacodynamics, and safety of VX-702, a novel p38 MAPK inhibitor, in rheumatoid arthritis: results of two randomized, double-blind, placebo-controlled clinical studies. Arthritis Rheum 60: 1232-1241.
29. Asgeirsdottir SA, Kamps JA, Bakker HI, Zwiers PJ, Heeringa P, et al. (2007) Site-specific inhibition of glomerulonephritis progression by targeted delivery of dexamethasone to glomerular endothelium. Mol Pharmacol 72: 121-131.
30. Moeller MJ, Soofi A, Hartmann I, Le Hir M, Wiggins R, et al. (2004) Podocytes populate cellular crescents in a murine model of inflammatory glomerulonephritis. J Am Soc Nephrol 15: 61-67.
31. Bariety J, Bruneval P, Meyrier A, Mandet C, Hill G, et al. (2005) Podocyte involvement in human immune crescentic glomerulonephritis. Kidney Int 68: 1109-1119.
32. Mundel P, Reiser J, Zuniga Mejia Borja A, Pavenstadt H, Davidson GR, et al. (1997) Rearrangements of the cytoskeleton and cell contacts induce process formation during differentiation of conditionally immortalized mouse podocyte cell lines. Exp Cell Res 236: 248-258.
33. Floege J, Burg M, Al Masri AN, Grone HJ, von Wussow P, (1999) Expression of interferon-inducible Mx-proteins in patients with IgA nephropathy or Henoch-Schonlein purpura. Am J Kidney Dis 33: 434-440.
34. Schneider A, Zhang Y, Guan Y, Davis LS, Breyer MD, (2003) Differential, inducible gene targeting in renal epithelia, vascular endothelium, and viscera of Mx1Cre mice. Am J Physiol Renal Physiol 284: 411-417.
35. Lan HY, Paterson DJ, Atkins RC, (1991) Initiation and evolution of interstitial leukocytic infiltration in experimental glomerulonephritis. Kidney Int 40: 425-433.
36. Polzer K, Soleiman A, Baum W, Axmann R, Distler J, et al. (2008) Selective p38MAPK isoform expression and activation in antineutrophil cytoplasmatic antibody-associated crescentic glomerulonephritis: role of p38MAPKalpha. Ann Rheum Dis 67: 602-608.
37. Stambe C, Nikolic-Paterson DJ, Hill PA, Dowling J, Atkins RC, (2004) p38 Mitogen-activated protein kinase activation and cell localization in human glomerulonephritis: correlation with renal injury. J Am Soc Nephrol 15: 326-336.
38. Stambe C, Atkins RC, Tesch GH, Masaki T, Schreiner GF, et al. (2004) The role of p38alpha mitogen-activated protein kinase activation in renal fibrosis. J Am Soc Nephrol 15: 370-379.
39. Fabian MA, Biggs WH, Treiber DK, Atteridge CE, Azimioara MD, et al. (2005) A small molecule-kinase interaction map for clinical kinase inhibitors. Nat Biotechnol 23: 329-336.
40. Song GY, Chung CS, Jarrar D, Chaudry IH, Ayala A, (2001) Evolution of an immune suppressive macrophage phenotype as a product of P38 MAPK activation in polymicrobial sepsis. Shock 15: 42-48.
41. van der Veen BS, Chen M, Müller R, van Timmeren MM, Petersen AH, et al. (2011) Effects of p38 mitogen-activated protein kinase inhibition on anti-neutrophil cytoplasmic autoantibody pathogenicity in vitro and in vivo. Ann Rheum Dis. 2011 Feb 70(2): 356-65.